Full text is available at the source.
Towards enhancing the predictive value of the microbiota for cancer immunotherapy
Improving how gut bacteria predict cancer immunotherapy success
AI simplified
Abstract
A two-tier model based on gut microbiota composition may help distinguish between responder and non-responder cancer patients to immune checkpoint inhibitors.
- The gut microbiota is increasingly recognized as a factor influencing responses to immune checkpoint inhibitors.
- Discriminating between responder and non-responder patients remains a challenge in clinical settings.
- The proposed model utilizes gut microbiota composition to categorize patients based on their likelihood of responding to treatment.
- Findings may provide new avenues for using gut microbiota as a biomarker in cancer therapy.
AI simplified